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END OF PROJECT REPORT 
A. Programme/Project number: 
Programme Title: 
Project title: Apoptosis and Expression of Vascular Adhesion Molecules in 
Skin Microvasculature in Type 2 Diabetes Patients 
Programme Leader: Associate Professor Dr Hasnan Jaafar 
Project leader: 
Tel: 09-7664229 Fax: 09-7653370 
B. Describe your project and highlight major project achievement 
Firstly in this study, we were able to demonstrate that the microvascular changes and the 
expression of apoptotic and vascular adhesion markers in skin microvasculature in type 2 
diabetes patients. We were divided the microvascular changes to 3 parameters were 
endothelial cell counting (ECT), endothelial cell counting (ECe) and blood vessel counting 
(BVC). 
A sample 1 cm skin sample was taken from the incision site after proper consent. The skin 
sample were processed for Hematoxylin & Eosin (H&E) stain, Massons Trichrome (MT) and 
PAS stain and IHC with different of antibodies for apoptotic and adhesion molecules markers. 
The antibodies with different markers were procured from DAKO company. H&E stain, 
masson Trichrome and PAS stain were employed. The thickness of endothelial cell (ECT) and 
endothelial cell counting (ECC) were calculated. 
In these microvascular changes we able to demonstrate that in type 2 diabetes patients there 
were increasing of ECT, ECC and BVC. From these we found that H&E stain and MT stain 
can be used to detect the microvascular changes in diabetes patients and these finding can be 
used as an early identification investigation in diabetes patients for effective control. 
Our study also showed that the microvasculature in diabetes patients were associated with the 
level of fasting plasma glucose (FPG) and Hemoglobin Ale (AIC). These associations can give 
us some signal that the high level of FPG and AIC is a good indicator of microvascular 
changes in diabetes patients. Diabetes patients should be ware and try to control the level of 
glucose and AIC within normal range. 
We also found that the apoptotic markers such as Bax, Bcl-2, Caspase 3, caspase 7 and p53 
were highly express in diabetic patients. There were also can be seen the expression of 
vascular adhesion molecules such as VCAM and HLA. These kinds of antibodies react with 
the specific binding between antigen and antibodies. From these we can conclude that in 
diabetes patients the apoptosis process was involved in microvasculature. Its important 
indicator that apoptosis is a main indicator of cell death. Moreover we also seen the correlation 
between these types of antibodies have a good association with FPG and A I C. These findings 
give us main indicator that diabetes patients were develops cell death in blood vessel. So we 
noted that its can be useful as an early indicator to prevent the long term complications of 
diabetes that lead to amputations and other complications. 
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c. Objectives achievement 
• Original programme/project objectives after approval 
1- To identify the dysregulated apoptosis or role of apoptosis in the alteration of 
microvasculature cellular components in type 2 diabetes. 
2- To investigate the microvascular changes in the blood vessels in type 2 diabetes by 
TEM of skin sample 
3- To identify evidence of endothelial dysfunction by treating skin samples received 
from these patients and processing it for different markers like P-Selectin, Laminin, 
Fibronectin, Actin, ICAM, VCAM, HLA-Dr and macrophages. 
4- After identification of these vascular changes it will be possible t define better 
strategies for the early prevention of microvascular complications of diabetes. 
• Objectives Achieved (Please state the extent to which the project 
objectives were achieved) 
Objectives no. 1, 3 and 4 were fully completed. A skin biopsies and blood samples were taken 
from patients. The histological parameters of skin biopsies were classified base on the H&E 
stain, special stain & IHC. Light microscopic (LM) & IHC studies has been done on skin 
sections using different markers, vascular markers in type 2 diabetes, non diabetic and sibling 
patients. We successfully analyzed the results of H&E, special stain and IHC. We also 
observed the significant differences between histopathology parameters with biochemical 
markers. 
• Objectives not achieved (Please identify the objectives that were not 
achieved and give reasons) 
objective 2 was not fully successful after repeated attempts to analyze the thickness of 
endothelial cell structures due to poor sample processing and limited experience of our senior 
technologist to process the human skin tissue sample and prepare for our viewing. We 
obtained some results but not satisfactory. We decided to discard the objective. 
• Achievement of overall objectives 
D 
tJ 
Yes 
No 
D. Technology Transfer/Commercialisation Approach 
• Commercialisation potential 
GJ 
D 
Yes 
No 
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Please describe the approach planned to transfer/commercialize the results of 
the project 
Early detection of vascular markers causing alteration in microvasculature leading to long term 
complications of type 2 diabetes. 
Early identification of apoptotic changes which leads to the development of long term 
complications in type 2 diabetes patients. 
E. Benefits of the programme/Project (Please identify the actual benefits arising 
from the project as defined in Section III of the Application Form. For examples 
of outputs, organisational outcomes and sectoral/national impacts, please refer to 
Section III of the Guidelines for the Application of R&D Funding under IRPA) 
• Outputs of the programme/project and potential beneficiaries (Please 
describe specifically the outputs achieved and provide an assessment of 
their significance to users) 
I-New information to identify early markers of vascular dysfunction. 
2-Laboratory technique has been established to identify early markers of vascular dysfunction. 
3-New target group like sibling and its relation to Type 2 diabetics has been identified for 
better management. 
Organisational Outcomes (Please describe specifically the organisational benefits arising from 
the project and provide an assessment of their significance) 
The information and findings of this study can be used to identify early markers of vascular 
adhesion. We also developed new immunohistochemistry technique and markers for detect the 
vascular dysfunction. We have succeeded in new selection of the sibling and relation of type 2 
diabetics was identified for better management. 
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• National Impacts (If known at this point in time, please describe specifically 
the potential sectoral/national benefits arising from the project and provide an 
assessment of their significance) 
Our study had established to the fundamental knowledge of apoptosis processed that is 
relevant to complications of diabetes. This study also identify the early markers of apoptosis 
for vascular changes and its importance in monitoring diabetic complications so that it will 
help to reduce the financial burden of treating the complications and also loss of manpower 
due to prolonged stay in hospital. It's also important in defining better strategies for the type 2 
diabetes patients to prevent from long-term complications of diabetes. 
F. Assessment of programme/project structure 
• Project Team (Please provides an assessment of how the project team 
performed and highlight any significant departures from plan in either 
structure or actual man-days utilised). 
The project team members have performed excellently according to plan and able to 
overcome many problems and obstacles faced during the period of the study. 
• Collaborations (Please describe the nature of collaborations (local and 
international) with other research organisations and/or industry) 
Collaborations are mainly discussion and consultation among researchers locally 
and abroad on the techniques of immunohistochemistry and electron microscopy. 
G. Assessment of Research Approach (Please highlight the main steps actually 
performed and indicate any major departure from the planned approach or any 
major difficulty encountered) 
The main approaches used in the study are assessment of biochemical markers using 
patients plasma and serum, H&E and immunohistochemistry for blood vessels parameters and 
apoptotic markers as well as electron microscopy for endothelial cell assessment. Biochemical 
markers, blood vessel morphometry and apoptotic markers were successfully assessed. 
However, we faced difficulty in visualizing the endothelial cells on electron microscope due to 
technical difficulties in tissue processing and localization ofthe endothelial cells. 
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H. Assessment of the programme/Project Schedule (Please make any 
relevant comment regarding the actual duration of the programme/project and 
highlight any significant variation from plan) 
The project required an extension of three months from the actual duration as proposed. 
There is no significant variation from the original plan. 
I. Assessment of Programme/Project Costs (Please comment on the 
appropriateness of the original budget and highlight any major departure from the 
planned programme/budget) 
The financial allocation for the project was fully spent. 
J. Additional Programme/Project Funding Obtained (In case of involvement of 
other funding sources, please indicate the source and total funding provided) 
No 
K List and status of eqUipment purchased ( Status refers to the 
present condition of the eqUipment and its utilization) 
One Sony digital camera - it is in good working condition 
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L. Other Remarks (Please include any other comment which you feel is relevant for 
the evaluation of this programme/project) 
Nil 
M. Remarks by IRPA Institution Coordinator 
~p,d frjt-vl-· ~ ~~ + 
~~, '-cJ-- ~~ ~~ 
N. Remarks by Program Leader 
O. Remarks by Lead Institution Coordinator 
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P. Remarks by Monitoring Unit 
Date: 
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BENEFITS REPORT 
I. DESCRIPTION OF THE PROJECT 
A. Programme I Project Identification: 
Programme I Project Number: 06-02-05-3195 EA 011 
Programme Title: Apoptosis & Expression of Vascular Adhesion Molecules in 
Skin Microvasculature in Type 2 Diabetic. 
Programme Leader: Associate Prof Dr Hasnan Jaafar 
Project Leader: 
Tel: Ext 4229 Fax: 09-7653070 
B. Type of research 
Indicate the type of research of the project (Please see definitions in the 
Guidelines for completing the Application Form) 
Q Scientific research (fundamental research) 
o Technology development (applied research) 
o Product / process development (design and engineering) 
o Social/policy research 
C. Objectives of the project 
1. Socio-economic objectives 
Which socio-economic objectives are addressed by the project? (Please identify 
the Sector, SEQ Category and SEQ Group under which the project falls. Refer to the Malaysian 
R&D Classification System brochure for the SEQ Group code) 
Sector: 
SE~ Category: S 3010000 
SE~ Group and Code: S 3010100 and S 3010105 
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2. Fields of research 
The two main FOR Categories, FOR Groups, and FOR Areas of your 
project? (Please refer to the Malaysian R&D Classification System brochure for 
the FOR Group Code) 
a. Primary field of research 
FOR Category: Fll00000 
FOR Group and Code: F 1100700 
FOR Area: F 1100729 
b. Secondary field of research 
FOR Category: 
FOR Group and Code: 
FOR Area: 
D. Programme/Project duration 
What was the duration of the project? 
36 Months 
E. Programme/ Project manpower 
How many man-months did the project involve? 
36 Man-months 
F. Programme/ Project costs 
What were the total project expenses of the project? 
RM 188000.00 
G. Programme/ Project funding 
Which were the funding sources for the project? 
Funding sources Total Allocation (RM) 
IRPA 188000.00 
---'~~~' 
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II. DIRECT OUTPUTS OF THE PROGRAMME / PROJECT 
A. Technical contribution of the Programme/ Project 
1. What was the achieved direct output of the Programme / project: 
For scientific (fundamental) research projects? 
o Algorithm 
o Structure 
51 Data 
o Others, please specify: 
For technology development (applied research) projects: 
51 Method/technique 
o Demonstrator/prototype 
o Others, please specify: 
For product/process development (design and engineering) Programme/ projects: 
o Product/component 
o Process 
o Software 
o Others, please specify: 
For social/policy research : 
o Policy 
o Guidelines [j Others, please specify:lmportancQ of monitoring 1:l6Alc and ~aiting J2laima GIUCOiQ in 
diabetes to detect microvasculopathy injury 
2. How would you characterize the quality of this output? 
o Significant breakthrough 
51 Major improvement 
o Minor improvement 
B. Contribution of the project to knowledge 
1. How has the output of the project been documented? 
v Detailed project report 
Product / process specification documents 
Others, please specify: 
2. Did the project create an intellectual property stock? 
Category Intellectual Property 
Patent 
Copyright 
Trademark 
Industrial Design 
Others 
3. What are the publications available? 
Article(s) in national scientific publications 
Status 
Obtained Pending 
Granted Filed 
Granted Filed 
Obtained Register 
How many: 3 
Please Specify: 
Article(s) in international sCientific publications How many: 2 
Please Specify: 
Paper(s) national delivered at conferences/seminars How many: 6 
Please Specify: 
Paper(s) international delivered at conferences/seminars How many: 1 
Please Specify: 
Book How many: 
Please Specify: 
Others, please specify: 
4. How significant are citations of the results? 
Citations in national publications How many: 
Citations in international publications How many: 
Not yet v 
Not known 
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Filed 
III. ORGANISATIONAL OUTCOMES OF THE PROJECT 
A. Contribution of the project to expertise development 
1. How did the project contribute to expertise? 
D PhD degrees How many: 
Please List Name: 
Nationality: 
Area Expertise : 
Q Masters degrees How many: 
Please List Name: 
National ity: 
Area Expertise : 
D Research staff with new specialty How many: 
Please List Name: 
Nationality: 
Area Expertise : 
n Others, please specify: 
2. How significant is this expertise? 
Q One of the key areas of priority for Malaysia 
D An important area, but not a priority one 
B. Economic contribution of the project? 
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1 
Tengku Ahmad 
Malaysian 
Histopathology 
1. What is the expected economic contribution of the project materialized? 
D Sales of manufactured product / equipment 
D Royalties from licensing 
D Cost savings 
D Time savings 
D Others, please specify: 
2. What is the expected level of the economic contribution? 
D High economic contribution 
D Medium economic contribution 
D Low economic contribution 
Value: RM 
Value: RM 
Value: RM 
3. When has this economic contribution materialized? 
D Already materialized 
D Within one year of project completion 
D Within three years of project completion 
D Expected in thr~e years or more 
D Not applicable 
D Unsure of the time frame 
C. Infrastructural contribution of the project 
1. What infrastructural contribution has the project had? 
D New equipment Value: RM Please List: 
Q New / improved facility Investment: RM 60000.00 
Immunohistochemistry technique with a few new antibodies D New networking 
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D Others, please specify: ________________________ _ 
2. How significant is this infrastructural contribution for the organisation? 
o Not significant / does not leverage other projects 
Q Moderately significant 
D Very significant / significantly leverages other projects 
D. Contribution of the project to the organisation's reputation 
1. How has the project contributed to increasing the reputation of the 
Organization 
o Recognition as a Center of Excellence 
Q National award 
o International award 
Q Demand for advisory services 
D Invitations to give presentation in conferences 
U Visits from other organisations 
o Others, please specify: 
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2. How important is the project's contribution to the organization's reputation? 
o Not significant 
o Moderately significant 
Q Very significant 
IV. NATIONAL IMPACTS OF THE PROJECT 
A. CONTRIBUTION OF THE PROJECT TO ORGANISATIONAL LINKAGES 
1. Which kinds of linkages did the project create? 
o Domestic industry linkages 
o International industry linkages 
o Linkages with domestic research institution, universities 
D Linkages with international research institution, universities 
2. What is the nature of linkages 
D Staff exchanges 
D Inter-organisational project team 
D Research contract with a commercial client 
o Informal consultation 
D Others, please specify: - _________________ _ 
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B. SOCIAL-ECONOMIC CONTRIBUTION OF THE PROJECT 
1. Who are the direct customer/beneficiaries of the project output? 
Please list 
_Diabetic patients--1 doctor treating the patient, ____________ _ 
2. How has/will the socio-economic contribution of the project materialized? 
o Improvements in health 
D Improvements in safety 
D Improvements in the environment 
D Improvements in energy consumption/supply 
o Improvements in international relations 
D Others, please specify: -------------------
3. How important is this socio-economic contribution? 
o High social contribution 
D Medium social contribution 
D Low social contribution 
4. When has/will/this social contribution materialised? 
D Already materialized 
D Within one year of project completion 
D Within three years of project completion 
D Expected in three years or more 
D Not applicable 
GJ Unsure of the time frame 
V. REMARKS 
A. Remarks by IRPA Institution Coordinator 
v~ 7~J. rJ~ 
CAv.-~W~~ 
B. Remarks by Program Leader 
C. Remarks by Lead Institution Coordinator 
D. Remarks by Monitoring Unit 
Date: 
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Introduction 
Diabetes IS a very common metabolic disease and about 3% of the world 
populations i.e about 300 million of people around the world are suffering from diabetes. 
There are two common types of diabetes. The IDD.M (also known as type I diabetes) 
which accounts for about 10% of all diabetic who requires insulin for their treatment and 
control and NIDDM (also known as type 2 diabete~)'which accounts for about 70% of the 
diabetic population. Among the major complications of diabetes vasculopathy stands as a 
major one. Diabetic vasculopathy involves the large, medium and small sized blood 
vessels. 
Hyperglycemia and enzymatic glycosylation of proteins, lipid modulation and 
peroxidation (Kesavulu et al., 2000; Fried et al., 2001), macro and microvascular 
alterations (Werner et al., 2001) leads to long term complications in diabetes leading to 
neuropathy (Cameron et al., 2001 ;Feldman & Green. 1995). nephropathy (Vlassarn, 
I 997;I-Iebert, 200 I ;Narumi, 200 I), retinopathy (stechoInver CDA, 1996) and 
dermatopathy (Robbins & Cotran, 1999) in diabetes. Also there is more expression of 
vascular adhesion molecules like laminin, P Selectin, ICAM, VCAM (Espositocetal, 
2001 ;Joussen et ai, 2002;Martin et al., 2001; Betry-Coussot 2002), fibrinogen and factor 
VIII (DeElia et al., 2001;Wang, 2001), HLA DR, EGF, Macrophage (Kusterer et al., 
1999) leading to these microvascular alterations in diabetic patients.O 
Apoptosis or programmed cell death is an important event in different disease 
process and aging. Dysregulated apoptosis (too little or too much) is also thought to be 
, 
associated with the etiology of. microvascular changes (Pinti, 2002;Morit et aI., 
2002;Mohr et aI., 2002;Jesmine, 2002;Obrian et al., 2002, Khan et aI., 2002). Literature 
search found little work was done on the role of apoptosis in microvasculature of type 2 
diabetes patients. 
As alterations 111 the microvasculature IS directly related to the long term 
complications of diabetes, it is important to investigate the microvascular alterations in 
. 
diabetics particularly in relation to apoptosis and expression of adhesion molecules in 
type 2 diabetics as this is the most common form of diabetes in Malaysia . 
• 
Methodology 
.' 
Patients 
This cross-sectional study was conducted. in the Hospital Universiti Sains 
Malaysia (HUSM) from August 2003 to August 2005. Ethical approval was obtained 
from the Research & Ethical Committee, School pf Medical Sciences, Universiti Sains 
Malaysia on 14 May 2002. There were two groups of patients in this study: Group I was 
patients with DM type 2, group II was non-diabetes patients as a control patients and 
group III which there have a first-degree relation with parent who have a diabetes. These 
groups of patients were selected where they were admitted to HUSM for any surgical 
procedure. 
Fifty-nine patients were involved in Group I, 52 patients were involved in Group 
II and 15 patients were involved in group III. The skins and blood samples were taken 
from the patients after written consent was obtained. The skin samples were taken during 
surgery. The blood samples for FPG, A I C and FLP were taken at the time when patients 
were recovenng from surgery. These patients were matched with other 
parameters/cofounders such as age, race, gender, duration of diabetes, smoking, history, 
family history of diabetes and other diseases, occupation, social background, level of 
education, height, weight, bio mass index (8MI) and their past medical history . 
• 
• 
Skin biopsy 
The skin biopsy measlmng about 1 x2 cm2 was taken by the surgeon at the 
incision site and was immediately placed Il1 a universal bottle containing 10% 
formaldehyde. The skin sample was subsequently processed using a vacuum filtration 
tissue processor (Tissue-Tek VIP, E 150 S,akura,. '1996, Japan). The VIP software is 
programmable for up to nine different programs for use in the fixation, dehydration, 
clearing and paraffin infiltration of a variety of human, animal or plant tissue specimens. 
The processing schedule used with the automatic tissue processor will vary according to 
the type of tissue, the nature of work, the clearing reagent used and personal preferences. 
The tissues were embedded in paraffin, which was the final process of making a tissue 
section. Tissue blocks were trimmed and sectioned with microtome (Leica, Germany) to 
obtain 5-3 ~lm thick tissue sections. The ribbons of sectioned tissue were floated in a 
sooe water bath and 'fished' onto a microscopic slide. After embedding of skin biopsy, 
immediately performance to making skin biopsy block. The tissue remained in the 
paraffin and maintained under -6 °e to be freeze . 
List of detail antibodies were used in this study: 
Table 1 Apoptosis markers: 
Incubation 
Antibodies Supplier Dilution Positive controls 
time 
Bax DAKO Cytomation, 1 :200 Overnight Adenocarcinoma 
Jerman 
Bcl-2 DAKO Cytomation, ,'1: 100. I hr Breast carcinoma 
Jerman 
Von DAKO Cytomation, I: 100 I hr Tonsil 
Willebrand Jerman . 
Factor 
Caspase ,., DAKO Cytomatian, 1 :200 2 hr Tonsil j 
(CPP32) Jerman 
P53 DAKO Cytomation 1:25 1 hr - 2 hrs Tonsil 
I 
I 
Caspase 7 Chemicon I: I 00 2 hrs Hodgkin lymphoma 
Caspase 9 Chemicon I: 100 2 hrs Hodgkin lymphoma 
Fas Ligand DAKO 1 :30 2 hrs Breast carCInoma, 
Human prostate 
Table 2 Vascular adhesion molecules markers: 
Incubation 
Antibodies Supplier Dilution Positive controls 
time 
V-Cam DAKO 1:50 1 hI' - 2 hI's Tonsil I I 
Cytomation 
I 
P-Selectin DAKO 1:50 6 Ius I Tonsil J 
HLA-DR,DQ DAKO 1 :50 6 hI'S Tonsil J 
ICAM (CD 54) Chemicon 1:20 1 hI'S Tonsil J , 
--
• 
• 
H&E staining and histopathological assessment 
5-3 micrometer (J-lm) of tissue section was made form paraffin-embedding block. 
The sections were stained with haematoxylin-eosin (H&E), Masson Trichrome (MT), 
Periodic Acid Schiff (PAS). This technique followed the standard H&E, MT and PAS 
staining protocols of the Pathology Laboratqry, Scbool of Medical Sciences USM. The 
tissue sections were then reviewed for histopathological assessment and morphology of 
the cells. 
Immunohistochemistry technique 
The technique was performed to demonstrate the expression of each apoptotic 
markers: Bax, Bcl-2, Fas-Ligand, Von Willebrand Factor, Caspase 3 (CPP32), P53, 
Caspase 7. Caspase 9 and ICAM (CD 54). Vascular adhesion molecules markers: 
VCAM. P-Selectin. HLA DR-DQ and ICAM (CD54). Standard label streptavidin biotin 
method was used on formalin-fixed paraffin embedded tissue sections. 
In brief, tissue sections were deparaffinised in xylene and dehydrated. For the 
detection of apoptotic markers and vascular adhesion molecules slides were pretreated 
with Triss EDTA buffer (IOmM, pH 9.0) for 14 minutes in microwave oven heating. 
Subsequently, all sections were treated for 10 minutes with peroxidase blocking reagent 
(DAKO) to quench endogenous peroxidase activity and then incubated with primary 
antibodies and followed by rinsing with TBS (pH 7.2). For visualization, the slides were 
immersed in diaminobenzidine (DAB) Ib02 (DAKO) substrate Cor 5 minutes. and then 
followed by washing in distilled water. The slides were counterstained with Harris 
hacmatoxylin. dehydrated and mounted. To assess the specilicity of the reaction . 
• 
recommended positive controls and negative controls (incubation without pnmary 
antibody) were incubated. The antibody sources, recommended positive controls and 
dilutions are shown in Table l~nd 2. Staining intensity for each result was evaluated due 
to semi quantitative score as follows: 0 = no staining; 1 + = 1-10% positive staining, 2+ = 
11-50% positive staining, 3+ = >50% positive staining. Scoring 0 and 1 were classified as 
the negative expressions while 2 and 3 as the; positiye expressions. 
Blood vessel counting (BVC) and endothelial cell counting (ECC) 
The tissue sections were subjected to standard avidin biotin complex (ABC) 
immunohistochemical method for FVIII related antigen (12). The FVIII related antigen 
will stain blood vessels. The blood vessels in the dermis were counted under 5 high 
power fields (x400 magnification) and the means were recorded. The number of 
endothelial cells in each vessel was also counted and the mean was calculated. 
Measurement of endothelial cell thickness (ECT) 
To measure the endothelial cell thickness, the tissue sections were subjected to 
Periodic Acid Shiff (PAS) stain. Five blood vessels in the dermis were identified for each 
sample. The endothelial cell thickness of all endothelia present in the vessel was 
measured in micrometer (11m) using image analyzer (Leica) and the mean thickness was 
calculated. 
Blood collection 
From each patient, 5 ml fasting venous blood was obtained. Subsequently, 2.5 ml 
blood was aliquoted into a tube containing potassium ethylene diamine tetraacctic acid 
(EDTA) to determine glycated hemoglobin level (A 1 C). Another 2.5 ml blood was 
aliquoted into a tube containing sodium oxalate to determine FPG level. The plasma was 
subsequently separated after 3-minute centrifugation at 4000 rpm and was analyzed for 
FPO by automated enzymatic glucose oxidase method using commercial kits (RANOOX) 
, 
on Hitachi 912 autoanalyzer. All. samples were determined for quantitative glycated 
hemoglobin concentration using the OiaSTA T hem~globin Ale programme on the Bio-
Rad DiaST A T analyzer. Standard procedures recommended by OiaST A T hemoglobin 
Ale programme for analyzing HbAIC were fdllow~d. 
Statistical analysis 
Statistical Package for Social Sciences (SPSS) statistical software (version 12.0.1) 
was used for the analysis of the biochemical and histopathological data in this study. The 
distribution of all numerical variables was checked for normality and presented by mean 
(standard deviation, SO). To analyse the difference between group means, Student {-test 
for two groups (two independent means) was used for variables with normal distribution. 
To analyze the significance differences in categorical variable between group and the 
expression of vascular adhesion molecules and apoptosis markers the chi square was 
used. The difference of mean BVC, ECT and ECC were adjusted for age, fasting plasma 
glucose (FPO), glycosylated hemoglobin (A 1 C), systolic blood pressure (SBP), diastolic 
blood pressure (OBP), body mass index (BMI) and group, by Multiway Analysis of 
Variance (ANOVA). For correlation between biochemical and histopathological markers, 
the Bivariate Pearson correlation was used. Level of significance (a) was set at 0.05 and p 
value < 0.05 was accepted as significant. 
OBJECTIVE 
1- To identify the dysregulated apoptosis or role of apoptosis in the alteration of 
microvasculature cell~lar ~omponents in type 2 diabetes. 
2- To investigate the microvascular changes i~ the blood vessels in type 2 diabetes 
by TEM of skin sample 
3- To identify evidence of endothelial dysfunction by treating skin samples 
received from these patients and processing it for different markers like P-
Selectin, Laminin, Fibronectin, Actin, ICAM, YCAM, HLA-Dr and 
macrophages. 
4- After identification of these vascular changes it will be possible t define better 
strategies for the early prevention of microvascular complications of diabetes. 
RESULTS 
Table I shows the summary result .of biochemical markers, apoptosis markers, adhesion 
molecules and microvasculature in diabetes, control ~nd sibling patients. 
Group Biochemical Apoptosis Adhesion Microvasculature 
markers maikers. ' molecules 
DMVsC Bcl-2* , YCAM*, BVC* 
FBS* Caspase 3*, HLA* ECT* 
AIC* caspase 7*, ECC* 
p53*, Bax*, 
Sibling Vs C FBS* Bcl-2* - ECC* 
AIC* 
DM Vs Sibling FBS* BCI-2* , - BVC* 
AIC* Caspase 3*, ECT* 
Caspase 7*, ECC* 
p53* 
*Increased 
The table I shows the summary of the result between biochemical markers, 
apoptosis markers, adhesion molecules and microvasculature. All the result above 
was labeled by (*) as an increased of value. 
Table 3 Mean differences of biochemical markers between diabetes and control 
Diabetes Control Mean difference T-test . p-value 
Mean±SD , Mean±SD (95% CI) 
FBS 11.07 ±4.07 4.42± 1.04 -6.64 -10.37 P<O.OO I 
(-7.92,-5.36) 
TG 1.85± l.06 1.40±1.26 -0.45 -1.85 0.779 
(-,0.93,0.03 ) 
LDL 3 .2± l.67 3.31±1.34 -1.11 0.342 0.178 
(-0.55,0.77) 
HDL l.05±0.41 1.45±0.69 0.4 3.14 0.003 
(0.16,0.64 ) 
Choles 5.06±2.01 5.24±1.29 0.18 0.5 0.069 
(-0.54,0.9) 
HbAlc 9.49±2.25 5.04±0.04 -4.44 -10.38 P<O.OOl 
(-5.3,3.6) 
Table 4- Mean differences of biochemical markers between diabetes and control 
Diabetes Sibling Mean difference T-test p-value 
Mean ±SD Mean±SD (95% CI) 
FBS 11.1±4.1 5.0±0.6 6.0 5.3 P<O.OOI 
(3.8,8.3) 
TG 1.85±1.1 1.53± 1.0 -0.32 1.0 0.875 
(0.3,1.0) 
LDL 3.2±1.7 3.5±1.1 -0.3 -0.6 0.092 
(-1.3,0.7) 
HDL I.O±OA 1.1±0.3 -0.1 -0.6 0.681 
(-0.3,0.2) 
Choles 5.0±2.0 5.4±1.0 -0.3 -0.6 0.087 
(-1.5.0.8) 
HbA1c 9.5±2.2 14.1±33.4 -4.6 -1.0 P<O.OOI 
(-13.8,4.6) 
Table 5 Mean differences of biochemical markers between control and sibling 
Control Sibling Mean difference T-test p-value 
Mean±SD Mean±SD (95% CI) 
, 
FBS 4.42 ±1.04 5.33±0.63 -0.6 -2.55 0.015 
. (-l.09,-0.12) 
TG 1.40±1.26 1.53± 1.00 -0.13 -0.46 0.364 
(-0.9,0.64) 
LDL 3.31±1.33 3.Sl±'(11 -0.2 -0.46 0.364 
(-l.OS, 0.66) 
HDL 1.45±0.69 1. 12±0.33 0.33 2.25 0.3 
(0.03,0.62) 
Choles S.24±1.29 S.38± 1.03 -0.14 -'0.3 S 0.348 
(-0.92,0.65) 
HbAlc S.04±0.64 14.08±33.36 -9.04 1.49 0.002 
(-21.34,3.27) 
Biochemical markers 
There were significant differences of FBS and Al C between diabetic, control and sibling 
patients. The detail of results was shown in table 3. 4 and 5. 
Expression of apoptotic markers 
There were significant differences expression of Bax, Bcl-2, caspase 3, caspase 7 and p53 
between diabetes and control groups (table 1). While in diabetes and control there was 
only Bcl-2 expression. Bcl-2, caspase 3, caspase 7 and pS3 were highly expression 
between diabetes and sibling patients (Table I). 
Vascular adhesion molecules 
There were significant differences expression VCAM and HLA between Diabetes and 
control patients. While there "wen~ no significant differences between others groups 
(Table 1). 
Microvascular changes (BVC, ECC and ECT). 
There were significant differences of microvascular changes between diabetes with 
control and diabetes with sibling. While there were only ECC shown significant 
differences between sibling and control (Table 2). 
DISCUSSION 
Diabetes and Microvasculature 
, 
Diabetes is usually separated into two major types; non-insulin-dependent 
diabetes (NIOOM) and insulin-dependent diabetes. (lOOM). Most of the long-term 
complications of diabetes mellitus stalk from failure of the microvasculature. It has long 
been documented that microvascular disease und.erIies diabetic retinopathy as well as 
nephropathy. Recently, damage to the microvasculature has been a concern in diabetic 
cardiopathy (Poornima et. aI, 2006) as well as the pathogenesis of diabetic neuropathy 
(Sugimoto et. ai, 2000). Microangiopathy is not a singular process but involves different 
stages of development. In the development of diabetes, changes of microcirculation 
function are marked which may be reversible if the metabolic abnormality is normalized. 
Progressing and increasing of duration of diabetes causes structural adaptive changes to 
occur, 1110st obvious of which is basement membrane thickening, owing to buildup of 
extravascular matrix proteins. The thickening of the basement membrane is an novel 
discovery and have been demonstrated in the microvasculature of the eye (Fong et. ai, 
2004), kidney (ADA, 1998), muscle (Klein et. aI, 1987), and skin (Yasuda et. aI, 1990). 
Though its functional importance has been discussed, it is adequately prevalent 
after the duration of diabetes to be regarded as the ultrastructural hallmark of diabetes 
mellitus. Eventually, in many microvascular networks, complete failure of transfer 
function occurs possibly precipitated by microvascular occlusion. Such a terminal event 
outcome in areas of under perfusion is most well accepted fact in the retinal 
microcirculation. These areas of poor tissue nutrition may activate reparative mechanisms 
vvhich in the case of retinopathy may be damaging in themselves as the new vessels may 
develop into the vitreous of the eye and avoid the risk of bleeding and hence obscuring 
the light path to the retina. 
, 
Although it is normal to believe the microangiopathic complications as being of 
frequent origin in NIOOM and 100M and current data suggests that such a hypothesis 
requires qualification (Jaap & Tooke, 1995). Clinical observation reveals that the 
progression resulting in blindness commonly difft;rs in the two major forms of diabetes: 
proliferative retinopathy is the common cause of visual loss in 100M, whereas 
maculopathy is the major problem facing those with NIOOM. Similarly, although 
nephropathy prevalent in both types of diabetes it tends to run a slower course in 
NIOOM. 
Furthermore, it is well known that the prevalence of hypertension (in the absence 
of nephropathy) is much greater in NIOOM, as is the overall risk of arterial disease, 
possibly reflecting the expression of the insulin resistance syndrome, of'vvhich NIDOM is 
simply one part. As it becomes clearer that NIODM is a heterogeneous collection of 
conditions resulting from various degrees of insulin-resistance and beta cell failure, even 
the broad distinction between the two major types of diabetes may not be sufficient if we 
are to fully understand the nature of diabetic microangiopathy. 
Microvasculature & Apoptosis & Adhesion molecules 
Apoptosis is associated with the onset and development of diabetes. It has been 
demonstrated that free fatty acid (Lupi el. 01. 2002), c-Myc (Laybutt el. aI, 2002). 
oxidative stress (Gorogawa et. aI, 2002) high glucose (O'Brien cl. 01, 1997), and Fas 
(Savinovef. aI, 2003) induce apoptosis of pancreatic ~ cells, leading to the development 
of diabetes. Our study demonstrates that p53 was expressed in diabetic patients. Our 
result is in contrast to the study done by Abu EI-Asrar et ai., where they found that there 
was no expression of p53 in human diabetic retinas (Abu EI-Asrar et ai., 2004). 
, 
Recent data have also' shown increased expression of the Bax protein in human 
fatty streaks and advanced plaques (Maliat and Tedgui, 2000). Study done by Jude et ai., 
found that the expression of ICAM was detected in diabetes patients who have a 
macrovascular disease and they suggested~ that .tCAM may predict development of 
macrovascular disease in diabetes mellitus (Jude et aI., 2002). This result was in contrast 
to our result where we found that there was no expression of rCAM in diabetic patients. 
We noted that there were no significant differences expressions of P-Selectin and 
this result was parallel with study done by Jude et al (Jude et ai., 2002). HLA was found 
in type 1 diabetic patients. It was used to detect the insulitis, autoantibodies and genetic 
susceptibility in type 1 diabetes patients (Nakamura et aI., 2003). This result supported 
our finding that HLA was expressed in diabetic type 2. 
Biochemical markers & Association with apoptosis and microvasculature 
FPG and HbA lc are being used by clinicians for measuring the level of diabetes 
control. Interestingly our results showed that these two parameters also correlate with the 
level of microvascular changes in diabetes patients. Stratton et al (2000) reported similar 
findings. 
Among other factors that will determine the rate and progreSSIOn of diabetes 
microvascular changes are duration and magnitude of hyperglycemia and genetic 
determinants of tissue response to injury. Therefore, it can be safely assumed from our 
study that uncontrolled and long standing hyperglycemia in diabetes were highly related 
to the development of vascular complications. Due to changes in blood vessel and 
endothelial cells which indicated showed number of blood vessels, endothelial cells and 
also increased thickness of endothelial cells all of which indicate angiogenesis and 
activation of vascular time. .' 
Another aspect that should be acknowl~dged is the correlation between 
hyperglycemia and blood vessel abnormalities. Hyperglycemia will induce 
atherosclerotic changes and renal vascula( chang'es in diabetes nephropathy patients. 
Hyperglycemia may also contribute to reversible abnormalities in blood flow and 
vascular permeability in the eye and kidney very early in the course of diabetes, long 
before irreversible structural changes are evident. 
There might be some relationship between endothelial cell dysfunction and 
increased FPG and HbA lc . A few previous studies concentrated on endothelial 
dysfunction involving humans or animals. Researchers have found that endothelial cells 
play an important role in controlling the biochemical pathway of blood circulation. 
Kang and Johnson (2003) had proven in their study that endothelial growth factor 
played an important role in modulating microvascular loss. It has already been shown that 
endothelial dysfunction in diabetes patients are inter-related with glycemic control. 
The proposed mechanisms that caused such complications were impaired 
endothelium-dependent and endothelium-independent vasodilations resulting in reduced 
endothelial constitutive nitric oxide syntase expression. A final point to note is prolonged 
exposure of endothelial cells to high glucose also increases superoxide anion production. 
Endothelial cells depend on vascular endothelial growth factor for proliferation and 
survival, which is pivotal to stimulate angiogenesis. Overperfused nutritive capillary 
circulation and increased of few blood vessels of patients with diabetes Tepper ct al. have 
demonstrated neuropathy and our findings support the observation reported by them. This 
is another evidence to support the formation of new vessels observed in our study. 
Apoptotic cells usually exhibit a distinctive constellation of biochemical 
modifications that underlie such structural pathology. Some of these features may be seen 
in necrotic cells also, but other alterations are more specific. A specific feature of 
, , 
apoptosis is protein hydrolysis involving the activation of several members of a newly 
discovered family of cysteine proteases named caspases. Caspases cleavage of the 
nuclear scaffold and cytoskeletal proteins (together with protein cross-link'ing) underlies 
the distinctive nuclear and cytoplasmic structural alterations seen in apoptotic cells. 
Caspase activity also triggers endonucleases. 
Extensive proteins cross linking by transglutaminase activation converts 
cytoplasmic proteins into covalently linked shrunken shells that may break into apoptolic 
bodies. Apoptotic cells exhibit a characteristic breakdown of DNA into large SO-kilobase 
to 300-kilobase pieces. Subsequently, there is internucleosomal cleavage of DNA into 
oligonucleosomes in multiples of 180 to 200 base pairs by Ca2+ and Mg2+ dependent 
endonucleases. The fragments are visualized by agarose gel electrophoresis as DNA 
ladders. Endonuclease activity also forms the basis for detecting cell death by 
cytochemical techniques that recognize double-stranded breaks of DNA. However, 
internucleosomal DNA cleavage is not specific for apoptosis. Moreover. the ··smear" 
pattern of DNA fragmentation thought to be indicative of necrosis may be only a late 
autolytic phenomenon, and typical DNA ladders may be seen in necrotic cells as well. 
Bcl-2 family proteins play a critical role in the regulation of programmed cell 
death and apoptosis. Changes in the levels or bioactivities of these proteins are associated 
, 
with a variety of physiological .process where cell death occurs including fetal 
development, haematopoietic and immune cell di(ferentiation, oogenesis, mammary 
gland involution and normal cell turnover in the epidermis, gut and several other tissues. 
Moreover, pathological alterations in the exp'ressiQrl of Bcl-2 family proteins have been 
documented in cancer, autoimmunity, immunodeficiency, heart failure, stroke and other 
disease (Sprick & Walczak, 2004). 
Diabetes and sibling or relation of type 2 diabetes 
Interestingly in our study, we were including the sibling patients or relation with 
type 2 diabetic as comparison between diabetic and control patients. In this study we 
found that they also express apoptotic markers in the microvasculature when compare to 
diabetic and control patients. So far, there were no study have been done. This 
identification can be used as a routine investigation in diabetic patients for effective 
control of early microvascular alterations. This may well reduce long-term complications 
of diabetes. As the number of sample is small, a study with large sample size is 
advocated. However the results of the present study may be used as a baseline data for 
future similar work. 
Future role NO & Apoptosis 
The reactive oxygen species (ROS) will inactivate nitric oxide, converting it to 
peroxynitrite, which is a poten(~aso~onstrictor. Such enhanced breakdown of nitric oxide 
will cause endothelial dysfunction, which is represen~ed by elevated/raised endothelin-l 
level, the earliest marker for endothelial dysfunction. Nitric oxide (NO) is a 
multifunctional molecule that is synthesized by a f~rhily of enzymes, namely nitric oxide 
synthases (NOS). NO is implicated in several physiological functions within the 
microvascular environment, regulation of vascular tone, antiplatelet and anti leucocyte 
properties and modulation of cell growth. Several investigations have demonstrated the 
effects of NO on gene transcription. In this view, NO has also implicated in the apoptotic 
process. In our future study we would like to investigate the role of NO in 
microvasculature of apoptosis of diabetes patients. 
CONCLUSION 
, 
The increased expression of.apoptosis and vascular adhesion markers in diabetic 
subjects is in agreement with the promotion of cell d~ath. Whereas, the reduced of these 
• 
markers in control patients confers cell survival. The detailed mechanism for these gene 
expressions may help us to understand how it js involved in apoptosis in diabetic 
microvasculature complications. 
There is a strong relationship between Ale and FPO with the number of blood 
vessels and number of endothelial cells per unit area as well as endothelial cell thickness 
in type 2 diabetes. In this study A I C measurement was shown to be a good predictor for 
endothelial abnormalities, which in turn indicated endothelial dysfunction. Therefore 
good control of Ale level is essential to maintain glycemic control in order to slow down 
the development and progression of microvasculopathy, which are the leading calise of 
.. 
diabetes complications. 
These findings in this study will hopefully throw some light on the early 
manifestation of early manifestations of alterations in the microvasculature leading to 
long term complications in type 2 diabetes. There we can define better strategies for the 
prevention of long-term complications of type 2 diabetes . 
.. 
• 
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